ACCESS Study

Study Summary: A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments. This study will recruit participants who will complete Cobicistat study protocol specified visits. It will provide access to ARV medications for approximately 18 years until the study drugs become commercially available.

Sponsor: Gilead Sciences, Inc

Principal Investigator: Dr. Godfrey Kigozi

Study site: AMBSO-Masaka Research Site

Update: Submissions to Regulatory bodies